Study to Investigate Daily Symptom Variability, Symptom Effects on Morning Activities of Chronic Obstructive Disease
NCT01110564 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 515
Last updated 2011-01-28
Summary
The primary objective of this non-interventional study is to evaluate daily symptom variability in COPD patients. The secondary objectives are; to evaluate effects of COPD symptoms on the morning activities of patients, to determine therapeutic expectations of patients and physicians in COPD, to determine which and how frequent non-drug approaches are recommended in order to prevent COPD exacerbations, to define COPD patient profiles about the below-mentioned issues: Demographic characteristics, Disease characteristics, Concomitant diseases and implemented drug treatments. All patients, who apply to the study physicians and fulfill all patient selection criteria during patient enrolment period, will be included. Patients, who provide all of the following measures will be included in the study: To apply to a physician for outpatient treatment for any reason, Age over 45 years, being diagnosed with COPD, being a smoker or used to be a smoker once (\> 10 package years), to give consent for the use of their medical data. The patients that exhibit the following exclusion criteria will be excluded from the study: COPD exacerbations still on-going or experienced in the last 3 months (Exacerbation is defined as worsening of COPD symptoms leading to antibiotic and/or short-term oral steroid treatment and/or hospitalization or admission to the emergency unit.); Presence of lung cancer or an important respiratory disease such as bronchiectasis, pulmonary fibrosis, interstitial pulmonary disease, tuberculosis, sarcoidosis; Participation in an interventional clinical trial at present and Enrollment in this study once. In this study, patients will be recorded at their visit to the physician and there will be no follow-up thereafter.
Conditions
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Tulin Kuyucu · Sureyyapasa Chest Disease Hospital
Eligibility
- Min Age
- 45 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-04-30
- Primary Completion
- 2010-12-31
- Completion
- 2010-12-31
Countries
- Turkey (Türkiye)
Study Locations
More Related Trials
-
A 24-week Evaluation of GSK573719/Vilanterol (62.5/25mcg) and Components in COPD
NCT01313650 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Assess the Efficacy and Safety of AZD1981 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT00690482 ·Status: COMPLETED ·Phase: PHASE2
-
The Study Will Evaluate the Effect of AZD8683 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT01205269 ·Status: COMPLETED ·Phase: PHASE2
-
A 4 Week Study to Investigate the Safety and Tolerability of AZD5069 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT01233232 ·Status: COMPLETED ·Phase: PHASE2
-
28-day Repeat Dose Study of GSK573719
NCT01030965 ·Status: COMPLETED ·Phase: PHASE2
-
A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease
NCT06154837 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Safety And Anti-Inflammatory Effect Of SB681323 In Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT00144859 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluate the Efficacy and Safety of GSK573719 Delivered Via a Novel Dry Powder Inhaler in Subjects With COPD
NCT01387230 ·Status: COMPLETED ·Phase: PHASE3
-
A Study To Examine The Safety, Pharmacokinetics And Pharmacodynamics Of PF-03635659 In Patients With Chronic Obstructive Pulmonary Disease
NCT01033487 ·Status: COMPLETED ·Phase: PHASE2
-
Safety And Efficacy Of GSK233705 Plus Salmeterol Compared With 2 Active Comparators And Placebo In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT00422604 ·Status: COMPLETED ·Phase: PHASE2
-
A Randomized, Double Blind, Placebo Controlled, Incomplete Block, Crossover, Dose Ranging Study to Evaluate the Dose Response of GSK573719 Administered Once or Twice Daily Over 7 Days in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT01372410 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Dose-Response Relationship of Multiple Doses of GSK2269557 Administered as a Dry Powder to Chronic Obstructive Pulmonary Disease (COPD) Patients
NCT02130635 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate Long-term Effectiveness and Safety, Patient Characteristics and Subjective Patient-reported Outcomes of Dupilumab in Patients With Chronic Obstructive Pulmonary Disease (COPD) Under Real-world Conditions
NCT07052396 ·Status: RECRUITING
-
Chronicling the COPD Patient Journey and Change in COPD Symptoms, Quality of Life and Exacerbations Following Initiation of Budenoside/Glycopyrronium/Formoterol [BGF]
NCT06511193 ·Status: ACTIVE_NOT_RECRUITING
-
Oral Cyclosporine in Chronic Obstructive Pulmonary Disease
NCT00974142 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study to Evaluate the Effects of ACT-541468 on Respiration in Patients With Moderate Chronic Obstructive Pulmonary Disease
NCT03646864 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of Tiotropium on Eye Findings in the Treatment of Chronic Obstructive Pulmonary Disease
NCT06525051 ·Status: COMPLETED
-
A Study of MK0359 in Patients With Chronic Obstructive Pulmonary Disease (COPD)(0359-016)
NCT00482235 ·Status: COMPLETED ·Phase: PHASE2
-
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT00676052 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase II, Study To Evaluate The Efficacy And Safety Of PH-797804 In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD).
NCT00559910 ·Status: COMPLETED ·Phase: PHASE2
-
A Two Week Study to Assess the Tolerability of AZD9668 in Chronic Obstructive Pulmonary Disease (COPD) Patients
NCT00703391 ·Status: COMPLETED ·Phase: PHASE2
-
GSK573719 Dose Ranging Study in Chronic Obstructive Pulmonary Disease
NCT00950807 ·Status: COMPLETED ·Phase: PHASE2
-
Safety, Toleration and Efficacy of Single Inhaled Doses of PF-00610355 in Chronic Obstructive Pulmonary (COPD) Patients.
NCT00783406 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Investigate the Dose Response, Safety and Efficacy of Nebulized EP-101(SUN101) in Patients With Chronic Obstructive Pulmonary Disease (COPD): GOLDEN-1 Study
NCT01426009 ·Status: COMPLETED ·Phase: PHASE2
-
Study of SB681323 and Prednisolone on Biomarkers in COPD (Chronic Obstructive Pulmonary Disease) Patients
NCT00380133 ·Status: COMPLETED ·Phase: PHASE1